期刊文献+

新型抗uPAR人源化抗体的表达和活性检测 被引量:1

Expression and activity detection of the humanized anti-uPAR antibody
原文传递
导出
摘要 目的制备抗尿激酶型纤溶酶原激活物受体(uPAR)人源化抗体并初步检测它们与抗原的亲和能力。方法通过计算机辅助设计的结果,合成新型抗uPAR抗体的轻链和重链可变区基因序列,通过重叠PCR方法,拼接成完整的轻链和重链基因并克隆入pIRES双向表达载体。瞬时转染293T细胞,收取细胞上清,rProtein A亲和层析法纯化目的抗体,并进行SDS-PAGE和免疫印迹鉴定,采用Biacore3000技术检测抗体与抗原的结合能力。结果成功构建5种表达载体S1~S5,纯化的抗体在还原SDS-PAGE中表现为相对分子质量约为25×103和55×103两条带;免疫印迹分析表明,该人源化抗体可与羊抗人IgG特异性结合。Biacore3000实验结果表明,S2、S4和S5抗体与抗原具有良好的亲和活性,且亲和活性分别为1.74×10-8,1.49×10-8和1.05×10-8mol/L。结论成功构建并表达了5种抗uPAR人源化抗体,其中S2、S4和S5具有良好的抗原结合能力。 Objective To prepare the humanized monoclonal antibodies against urokinase-type plasminogen activator receptor(uPAR),and preliminarily detect their affinity to uPAR.Methods L and VH genes of humanized monoclonal antibodies against uPAR were designed by the computer and synthesized by overlap PCR.Genes encoding L and H chains were connected and then cloned into vector pIRES,a bicistronic expression vector.The recombinant plasmids were transfected into 293T cells,purified antibodies through rProteinA affinity chromatography,and further confirmed by Western-blotting.The affinity of the humanized antibodies to the uPAR was assessed by Biacore assay.Results Five expression vectors were constructed and the humanized monoclonal antibodies against uPAR were expressed and purified successfully.In reducing SDS-PAGE,the antibodies exhibited two bands of approximately 25×103 and 55×103,respectively.Western blotting assay showed that the humanized antibodies had recognition specificity to goat-human IgG antiserum.Biacore assay revealed that the humanized antibodies S2,S4,and S5 bound to uPAR with high affinity(1.74×10-8mol/L,1.49×10-8mol/L,and 1.05×10-8mol/L,respectively).Conclusion Five humanized monoclonal antibodies against uPAR have been successfully constructed and expressed,and antibodies S2,S4,and S5 retain high affinity for uPAR.
出处 《军事医学》 CAS CSCD 北大核心 2011年第4期258-261,共4页 Military Medical Sciences
关键词 受体 尿纤溶酶原激活物 人源化抗体 瞬时表达 receptors urinary plasminogen activator humanized antibody transient expression
  • 相关文献

参考文献12

  • 1孙思凡,靳彦文,李平,曹诚,张部昌.新型抗EGFR人源化抗体基因的构建和表达[J].军事医学科学院院刊,2009,33(6):526-530. 被引量:1
  • 2师明磊,胡显文,陈惠鹏,高丽华,李世崇.抗CD20嵌合抗体的表达与活性检测[J].中国生物工程杂志,2005,25(7):34-39. 被引量:4
  • 3吕正华,栾信庸.尿激酶型纤溶酶原激活物系列与肿瘤转移[J].国外医学(肿瘤学分册),2005,32(3):179-182. 被引量:3
  • 4陈立慧,宋海峰,刘秀文.治疗性人源化单克隆抗体研究进展[J].中国新药杂志,2004,13(7):590-594. 被引量:10
  • 5沈倍奋.抗体药物研究进展[J].第二军医大学学报,2002,23(10):1047-1049. 被引量:17
  • 6Sai D,David HG,Daniel RH,et al.Antagonistic anti-urokinaseplasminogen activator receptor (uPAR)antibodies significantlyinhibit uPAR-mediated cellular signaling and migration. Journal of Biological Chemistry . 2010
  • 7Colomer R,Shamon LA,Tsai MS,et al.Herceptin: from the bench to the clinic. Cancer Investigation . 2001
  • 8Sambrook,J.,Fritsch,E. F.,Maniatis,T.Molecular cloning: a laboratory manual. . 2001
  • 9Plesner T,Behrendt N,Ploug M,et al.Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells . 1997
  • 10N. Behrendt,E. Ronne,K. Dano.Domain interplay in the urokinase receptor-requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. Journal of Biological Chemistry . 1996

二级参考文献66

  • 1胡显文,陈惠鹏,汤仲明,马清钧.生物制药的现状和未来(一):历史与现实市场[J].中国生物工程杂志,2004,24(12):95-101. 被引量:37
  • 2Graecone G. EGFR inhibitors in the treatment of lung cancer [J]. EJC Supplements, 2003, 1 (5) :S106.
  • 3Baselga J. EGFR therapies in other tumor types [J]. EJC Suppl, 2003,1 (5) :S107.
  • 4Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cell [J]. In Vivo,2005,19( 1 ) :237 -245.
  • 5Rose WC, Wild R. Therapeutic synergy of oral taxman BMS275183 and cetuximab versus human tumor xenografts [ J ]. Clin Cancer, 2004,10(21 ) :7413 -7414.
  • 6Mial L, Fan Z, Andratschke NH, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies [ J]. Int J Radiat Oncol Biol Phys,2004,58 (3) :966 - 971.
  • 7Iwahashi M, Milenic DE, Padlan EA, et al. CDR substitutions of a humanized monoclonal antibody ( CC49 ) : contributions of individual CDRs to antigen binding and immunogenicity [ J ]. Mol Immunol, 1999,36 ( 15 - 16 ) : 1079 - 1091.
  • 8Kashmiri SV, Iwahashi M, Tamura M, et al. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49 [ J ]. Crit Rev Oncol Hematol, 2001,3 (8) :3 - 16.
  • 9Leung SO, Goldenberg DM, Dion AS. Construction and characterization of a humanized, internalizing, leukemia/lymphoma antibody, L12[J]. Mol Immunol,1995,32( 17 - 18) :1413 - 1427.
  • 10Messersmith WA, Hidalgo M. Panitumumab, a monoclonal antiepidermal growth factor receptor antibody in colorectal cancer: another one or the one[ J] ? Clin Cancer Res, 2007,13 (16) :4664 - 4666.

共引文献30

同被引文献27

  • 1K6hler G, Milstein C. Continuous culture of fused cells secreting antibody d predefined specificity[J]. Nature, 1975, 256 (5517): 495-497.
  • 2Demarest S J, Glaser SM. Antibody therapeutics, antibody engineer- ing, and the merits of protein stability[J]. Curr Opin Drug Diseov Bevel, 2008, 11 (5) : 675-687.
  • 3Schneider CK. Monoclonal antibodies--regulatory challenges [J]. Curr Phann Biotechnol, 2008, 9 (6) : 431-438.
  • 4Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody[J]. Nature, 1984, 312(5995): 643 -646.
  • 5Siddiqui MZ. Monoelonal antibodies as diagnostics :" an appraisal [J]. Indian J Pharm Sci, 2010, 72( 1 ) : 12-17.
  • 6Nakano K, Ishiguro T, Konishi H, et-al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization [J]. Antieaneer Drugs, 2010, 21 (10) : 907-916.
  • 7Harding FA, Stickler MM, Razo J, et al. The immunogenicity of hu- manized and fully human antibodies: residual immunogenicity re- sides in the CDR regions[J]. MAbs, 2010, 2(3) : 256-265.
  • 8Kashmiri SV, De Pascalis R, Gonzales NR, et al. SDR grafting--a new approach to antibody humanization[J]. Methods, 2005, 36 (1) : 25-34.
  • 9Sehlin D, Hedlund M, Lord A, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-otl3 antibodies[J]. Neurodegener Dis, 2011, 8(3): 117-123.
  • 10Kim KS, Kim HJ, Han BW, et al. Construction of a humanized anti- body to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization[J]. Bioehem Biophys Res Commun, 2010, 396(2) : 231-237.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部